178 related articles for article (PubMed ID: 9285550)
21. Epstein-Barr virus associated post-transplantation lymphoproliferative disorder with hemophagocytosis in a child with Wiskott-Aldrich syndrome.
Wang IJ; Lu MY; Chiang BL; Lin WC; Lin DT; Lin KH
Pediatr Blood Cancer; 2005 Sep; 45(3):340-3. PubMed ID: 15547918
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus and bone marrow transplantation.
Caldas C; Ambinder R
Curr Opin Oncol; 1995 Mar; 7(2):102-6. PubMed ID: 7756374
[TBL] [Abstract][Full Text] [Related]
23. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
[TBL] [Abstract][Full Text] [Related]
24. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus-associated lymphoproliferative disorder after unrelated bone marrow transplantation in a young child with Wiskott-Aldrich syndrome.
Sasahara Y; Kawai S; Itano M; Kumaki S; Fujie H; Minegishi M; Tsuchiya S; Konno T
Pediatr Hematol Oncol; 1998; 15(4):347-52. PubMed ID: 9658436
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
27. Alpha-interferon therapy for lymphoproliferative disorders developing in two children following bone marrow transplants.
Trigg ME; de Alarcon P; Rumelhart S; Holida M; Giller R
J Biol Response Mod; 1989 Dec; 8(6):603-13. PubMed ID: 2480993
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
30. Late onset Epstein-Barr virus-associated lymphoproliferative disease after allogeneic bone marrow transplant presenting as breast masses.
Abhyankar SH; Chiang KY; McGuirk JP; Pati AR; Godder KT; Welsh JA; Waldron RL; McElveen JL; Henslee-Downey PJ
Bone Marrow Transplant; 1998 Feb; 21(3):295-7. PubMed ID: 9489654
[TBL] [Abstract][Full Text] [Related]
31. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
[TBL] [Abstract][Full Text] [Related]
32. Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children.
Fletcher BD; Heslop HE; Kaste SC; Bodner S
Pediatr Radiol; 1998 Jul; 28(7):492-6. PubMed ID: 9662565
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic T cells and immunotherapy.
Kitchingman GR; Rooney C
Pediatr Radiol; 1998 Jul; 28(7):489-91. PubMed ID: 9662564
[TBL] [Abstract][Full Text] [Related]
34. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens.
Peres E; Savasan S; Klein J; Abidi M; Dansey R; Abella E
J Clin Microbiol; 2005 Jul; 43(7):3540-3. PubMed ID: 16000501
[TBL] [Abstract][Full Text] [Related]
35. Prolonged remission of Epstein-Barr virus associated lymphoma secondary to T cell-depleted bone marrow transplantation.
Lyttelton MP; Browett PJ; Brenner MK; Norton JD; Kolman JL; McGee JO; Hamilton-Dutoit S; Hoffbrand AV; Prentice HG
Bone Marrow Transplant; 1988 Nov; 3(6):641-6. PubMed ID: 2850832
[TBL] [Abstract][Full Text] [Related]
36. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
Smith CA; Ng CY; Heslop HE; Holladay MS; Richardson S; Turner EV; Loftin SK; Li C; Brenner MK; Rooney CM
J Hematother; 1995 Apr; 4(2):73-9. PubMed ID: 7633844
[TBL] [Abstract][Full Text] [Related]
37. Lymphocytosis of donor origin in cerebrospinal fluid, and marrow aplasia after donor leukocyte infusion for EBV-lymphoproliferative disease.
Gharpure V; Rubin L; Amlin J; Emanuel D; Schroeder W; Davidson A; Hromas R; Cornetta K
Bone Marrow Transplant; 1996 Jul; 18(1):221-4. PubMed ID: 8832021
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment with rituximab and donor lymphocyte infusions for fulminant EBV-associated lymphoproliferative disorder that developed 14 years after unrelated BMT.
Kawaguchi T; Tsukamoto S; Ohwada C; Takeuchi M; Muto T; Tanaka S; Sakai S; Takeda Y; Abe D; Sakaida E; Shimizu N; Yokote K; Iseki T; Imadome KI; Nakaseko C
Bone Marrow Transplant; 2011 Dec; 46(12):1583-5. PubMed ID: 21278799
[No Abstract] [Full Text] [Related]
39. Isolated central nervous system Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Watanabe A; Yoshida S; Kasahara Y; Takachi T; Ogawa A; Asami K
Pediatr Blood Cancer; 2011 May; 56(5):871-2. PubMed ID: 21370426
[No Abstract] [Full Text] [Related]
40. Overview of posttransplant B-cell lymphoproliferative disorders.
Swinnen LJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):21-5. PubMed ID: 10561014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
